Table 1.
Characteristics of cohorts.
| Cohort | IVIG | Control | DMT |
| Number of patients | 51 | 51 | 22 |
| Age (years) | 31.4 (±4.35) | 30.3 (±4.33) | 29.9 (± 2.78) |
| Duration of MS years (SD) | 5.7 (±4.05) | 4.6 (±3.18) | 5.4 (± 2.78) |
| RRMS | 48 | 49 | 21 |
| SPMS | 3 | 2 | 1 |
| EDSS > 4 | 7 | 4 | 1 |
| DMT before pregnancy | 36 | 19 | 22 |
| Pregnancy with DMT | 19 | 6 | 13 |
| Total time without DMT/years (SD) | 1.96 (± 1.50) | 3.93 (± 2.96)∗∗∗ | 0.8 (±0.38) |
| Number of postpartum relapses in the first 3 months n/% |
7/13.7 | 16/31.4 | 4/18.2 |
| ARR before(SD) | 0.91 (±0.63) | 0.97 (±0.72) | 0.79 (±0.72) |
| ARR I (SD) | 0.55 (1.39) | 0.55 (± 1.39) | 0.35 (± 1.17) |
| ARR II (SD) | 0.16 (±0.78) | 0.24 (±0.95) | 0 |
| ARR III (SD) | 0.24 (±0.95) | 0.16 (±0.78) | 0.18 (±0.85) |
| ARR 1 postpartaL(SD) | 0.56 (± 1.46) | 1.28 (± 1.90) | 0.87 (± 1.57) |
DMT, disease modifying therapy; IVIG, intravenous immunoglobulin application; MS, multiple sclerosis; RRMS, relapse remitting multiple sclerosis; SPMS, secondary progressive multiple sclerosis. Data are given as mean ±SEM, respectively, of total number.
∗∗∗, p50.001 of the ANOVA between the three cohorts. Age, duration and total time is given in years.